常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-13.27/-8.81
|
|
企業價值
42.27M
|
| 資產負債 |
|
每股賬面淨值
11.67
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
3.95M
|
|
每股收益
2.66
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘:2025/11/16 08:35 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others. |

6.66 
